A Randomised, Single-Blind, Placebo-Controlled, Phase IIa Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 During Four Weeks in T2DM Subjects Treated With Insulin.
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2012
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 06 Dec 2010 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 17 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 17 Sep 2009 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.